Business PerformanceRevenues reflected another quarter of solid growth from its Digestive Health business, while its Pain Management division continued to show some improvement, despite ongoing headwinds.
EarningsBoth total sales and adjusted EPS came in ahead of Street expectations, with the latter more pronounced due to the company's efforts in cost management.
Financial GuidanceManagement reiterated full-year 2024 guidance on both the top and bottom lines, calling for sales of $685-$705 mln and EPS of $1.30-$1.45.